Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931440 | 0.84 | SPHK2 (0.64) | POLBL3MBTL1SPHK2PDK2ROCK2 | |
| SCHEMBL11447207 | 0.84 | SPHK2 (0.64) | POLBL3MBTL1SPHK2PDK2ROCK2 | |
| SCHEMBL591348 | 0.84 | HRH3 (0.57) | — | |
| SCHEMBL28044444 | 0.84 | HRH3 (0.57) | — | |
| SCHEMBL591304 | 0.84 | HRH3 (0.57) | — | |
| SCHEMBL17584872 | 0.82 | SPHK2 (0.55) | POLBL3MBTL1SPHK2PDK2ROCK2 | |
| SCHEMBL10194843 | 0.82 | SPHK2 (0.55) | POLBL3MBTL1SPHK2PDK2ROCK2 | |
| SCHEMBL966970 | 0.82 | SPHK2 (0.55) | POLBL3MBTL1SPHK2PDK2ROCK2 | |
| SCHEMBL17600731 | 0.82 | POLB (0.53) | POLBL3MBTL1SPHK2PDK2ROCK2 | |
| SCHEMBL17600735 | 0.82 | POLB (0.53) | POLBL3MBTL1SPHK2PDK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059517-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | Biovitrum AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025800-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103141-A1 | New compounds | GPR119, GPR3, GPR4 | POLB 4644/4885L3MBTL1 4778/4885SPHK2 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.